MILNACIPRAN

Milnacipran Information

Milnacipran is a selective inhibitor of the uptake of both norepinephrine and serotonin. Its actions concentrate on these two very important neurotransmitters, as for the prevention of the uptake of each 3 molecules of norepinephrine it prevents the uptake of 1 molecule of serotonin. However, scientists have not been able to fully understand the exact mechanism in which the administration of Milnacipran is able to effectively ease the symptoms of fibromyalgia, as the inhibitory action that this product has on central pain is still unclear. This medical product can be purchased under the form of tablets.

Milnacipran Indications

This product has been recently approved by the FDA for use in the case of patients who have been diagnosed with fibromyalgia. This product can also be employed in the clinical management of chronic pain and also moderate and / or severe depression. If you think that you could benefit from a therapeutic course with Milnacipran you should seek further information concerning the risks and benefits that are associated with a therapy with this medication. Your personal physician can give you such medical data and can tell you whether this pharmaceutical product is indeed the best solution for your current medical issue.

Milnacipran Warnings

While the FDA has approved the use of Milnacipran in the case of adult patients, children and adolescents under the age of 15 should not be allowed to start a therapy course with this medication. The safety of use of this product in the case of females who are pregnant or nursing an infant is debatable. Therefore, such patients should avoid the use of Milnacipran. Individuals who are known to be allergic to any of the components of this product should seek an alternative way of managing their current medical condition. The same advice is valid in the case of patients who are suffering from severe renal or kidney disorders.

Milnacipran Intake Guidelines

The tablets of Milnacipran should be taken in orally. One can take his or her prescribed doses of this medication on a full or on an empty stomach, as meals do not interfere in any way with the absorption of the ingredients of Milnacipran. This drug is not known to cause stomach upset.

Milnacipran Dosage

You should not be surprised if you see that your medical provider prescribes you different dosage schedules during the various stages of your treatment course with Milnacipran. The starting dose is of about 12.5 mg per day, and then it gradually increases up to 100 mg per day. As such, after 7 days of therapy, the patient will probably be advised to use 100 mg of Milnacipran per day (the use of two tablets of 50 mg per day is considered appropriate). Depending on your organism’s response to the therapy with this medication, your PD can choose (later on) to diminish or to increase your daily dose. You are not entitled to make any adjustments to your dosing routine without the direct consent of a medical specialist.

Milnacipran Overdose

Very few cases of severe over-dosage with Milnacipran have been reported so far. Luckily, none of them was lethal and they all successfully responded to the therapy routine that is normally applied in such cases. Nevertheless, rapid medical intervention is necessary in order to reduce the patient’s risks of developing any permanent symptoms / damage. We strongly advise all individuals to seek emergency medical attention as soon as they suspect to be suffering from over-dosage with Milnacipran.

Milnacipran Missed Dose

Missed doses of Milnacipran will probably impair the effectiveness of your therapy, especially if they occur on a repeated basis. In order to prevent this, you should refer to your personal health care provider and learn the correct, professional way in which such a condition can be corrected. If you are not comfortable with your current dosing routine (it does not match your daily schedule), you should ask your PD to make the necessary modifications.

Milnacipran Side Effects

The extensive use of Milnacipran can lead to the developing of several unpleasant adverse manifestations that are widely referred to as the side effects of this product. Such unpleasant symptoms mainly appear in the case of individuals who have failed to employ their prescribed doses of this medication in a proper manner. Most of these symptoms can be effectively managed with the help of a medical specialist; this is why we recommend all patients who develop any unpleasant manifestations during their therapy course with Milnacipran to immediately alert their medical provider and ask him or her for further instructions. While some of the side effects of this medication are temporary, and last only for a couple of days, long-lasting clinical manifestations have also been reported. The patients who present such symptoms should be kept under close medical supervision.

The most common side effects of Milnacipran include the following manifestations: nausea, constipation, headache, hyperhidrosis, hot flush, palpitations, hypertension, dry mouth, rapid heart beat, and so on. You should be well aware of the fact that these are not all the symptoms that can arise during your therapy course with Milnacipran. For more detailed information (a more complete list of potential side effects), you can refer to your PD or simply read the product’s label.

Milnacipran Drug Reactions

Patients who are currently following a therapy course with reversible MAO-A-Inhibitors (such as Toloxaton, Moclobemid), Norepinephrine, Epinephrine, Clonidine and other similar products will probably not be allowed to start using Milnacipran. Severe interactions can occur if such a concomitant therapy is applied. Your local pharmacist, a nurse or your personal medical provider can offer you further information about this matter. It is important to learn as much as possible about the pharmaceutical interactions that can affect your current therapy course with Milnacipran.

Buy Milnacipran

It is available through our Online Pharmacy Escrow Service or at any Canada Pharmacy selling Online Prescriptions.